By examining more than 3,600 postmortem brains, researchers have found that the progression of dysfunctional tau protein drives the cognitive decline and memory loss seen in Alzheimer’s disease.
The struggle to show meaningful progress in treatment of Alzheimer's disease via clearance of amyloid has fueled significant investment into alternative hypotheses regarding the disease process. The biochemistry of Alzheimer's - andShow More Summary
By examining more than 3,600 postmortem brains, researchers at Mayo Clinic's campuses in Jacksonville, Florida, and Rochester, Minnesota, have found that the progression of dysfunctional tau protein drives the cognitive decline and memory loss seen in Alzheimer's disease.
A promising new natural treatment for Alzheimer's disease is moving toward clinical trials. This will be a major step forward as there is nothing on the market that slows the progression of Alzheimer's; natural products chemist has patented a botanical compound, withanamides.
Researchers have identified a promising new target in the battle against certain neurological diseases. A protein known as TREM2 has been proven effective in clearing away unwanted debris in the brain, the unchecked buildup of which can lead to both Alzheimer's disease and multiple sclerosis (MS)... Show More Summary
Highlighting a potential target in the treatment of multiple sclerosis (MS) and Alzheimer's disease, new research suggests that triggering a protein found on the surface of brain cells may help slow the progression of these and other neurological diseases.
Can the Alzheimer's caregiver make a difference in the progression of Alzheimer's disease? Is it possible that Alzheimer's caregiver love can be as effective, or more effective, than the drugs that are currently available for the treatment...Show More Summary
Our susceptibility to disease depends both on the genes that we inherit from our parents and on our lifetime experiences. These two components -- nature and nurture -- seem to affect very different processes in the context of Alzheimer's disease. A new study of epigenomic modifications reveals the immune basis of Alzheimer's disease.
A molecular chaperone has been found to inhibit a key stage in the development of Alzheimer’s disease and break the toxic chain reaction that leads to the death of brain cells. By Alzheimer's Reading Room A molecule that can block the...Show More Summary
Amyloid-? is a species of misfolded protein that forms solid clumps in the brain. Its accumulation and related processes are associated with the progression of Alzheimer's disease. This isn't a slow progress of gathering waste, however, as levels of amyloid-? are quite dynamic. Show More Summary
Efforts to treat Alzheimer's disease by clearing the amyloid beta (A?) deposits and related precursors associated with the progression of the condition have proven to be challenging, beset with failures and complications. Wherever there...Show More Summary
Many people have seen the slow decline of a relative or friend with Alzheimer’s Disease. Sometimes the disease even strikes the relatively young and progresses rapidly. It’s terrifying to most people because it is non-discriminatoryShow More Summary
Alzheimer's disease (AD) progresses inside the brain in a rising storm of cellular chaos as deposits of the toxic protein, amyloid-beta (A?), overwhelm neurons. An apparent side effect of accumulating A? in neurons is the fragmentation...Show More Summary
Though shot in the stolidly inconspicuous style of a low-rated cable drama, Still Alice is rarely anything short of compelling, in part because its sense of progression and scale offers such a distinctively unsentimental take on the terminal-countdown tearjerker. Show More Summary
Aricept is not a cure for Alzheimer's disease, and it does not stop Alzheimer's. When it works well, it is designed to slow the progression of Alzheimer's and improve behavior. Bob DeMarcoAlzheimer's Reading Room The use of Aricept for Alzheimer's disease is controversial. Show More Summary
"Inadequate funding remains the single most important impediment to progress in achieving the research goal of the Alzheimer's National Plan." By Bob DeMarco Alzheimer's Reading Room The U.S. Government has initiated a major effort to prevent and effectively treat Alzheimer's disease by 2025. Show More Summary
Most of the research community proceeds under the assumption that amyloid, deposits of misfolded proteins that form in tissues, is a causative agent in Alzheimer's disease. Amyloid levels rise with age, probably due to progressive failure of clearance mechanisms. Show More Summary
A new preclinical study indicates that THC, the active ingredient in marijuana, may slow or halt the progression of Alzheimer's disease. Alzheimer's Reading Room THC (Tetrahydrocannabinol) is the active ingrient in marijuana that produces a psychoactive reaction. Show More Summary
Tampa, FL (Aug. 26, 2014) -- Extremely low levels of the compound in marijuana known as delta-9-tetrahydrocannabinol, or THC, may slow or halt the progression of Alzheimer's disease, a recent study from neuroscientists at the University...Show More Summary
Research will look to produce compound derivatives of punicalagin for a drug that would treat neuro-inflammation and slow down the progression of Alzheimer's disease, scientists report. The onset of Alzheimer's disease can be slowed and some of its symptoms curbed by a natural compound that is found in pomegranate. Show More Summary